EU6 Stock Chart & Stats
€0.19
>-€0.01(-0.97%)
At close: 4:00 PM EDT
€0.19
>-€0.01(-0.97%)
Day’s Range― - ―
52-Week Range€0.17 - €1.22
Previous CloseN/A
Volume0.00
Average Volume (3M)7.91K
Market Cap
€37.30M
Enterprise Value€47.81M
Total Cash (Recent Filing)€5.60M
Total Debt (Recent Filing)€4.36M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Nov 12, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding55,971,336
10 Day Avg. Volume7,575
30 Day Avg. Volume7,911
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)3.86
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.45Price Target Upside2241.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.39
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Validation Of PDS0101The reported Phase 2 results provide meaningful clinical validation for PDS0101 in HPV16-associated head and neck cancer. A favorable efficacy and safety profile can improve partnering prospects, support future regulatory development, and strengthen the platform’s credibility over the next several quarters.
PDS0301 Colorectal Cancer ProgressEncouraging PDS0301 data in difficult-to-treat metastatic colorectal cancer gives the company a potentially differentiated lead asset and a clear development priority. Progress toward a registrational Phase 3 program could improve strategic value and concentrate scarce resources on the strongest clinical opportunity.
Strategic Financing And Debt RetirementRetiring the Yorkville note removes a stated debt obligation, while the PIPE supplies capital for working capital and continued clinical development. Nant’s investment and license-negotiation right also provide external validation and may improve access to strategic funding for key programs.
Bears Say
Pre-revenue And Persistent LossesWithout recurring product revenue, PDSB remains dependent on financing, collaborations, or future milestones to fund operations. Persistent losses and negative cash generation reduce internal funding capacity and make continued clinical progress vulnerable to capital availability over the next several quarters.
Severely Weakened Balance SheetNegative equity and substantially higher debt materially weaken financial flexibility and increase solvency and refinancing pressure. This balance-sheet deterioration can constrain investment in the pipeline, raise financing costs, and leave less room to absorb setbacks in clinical or partnering plans.
Dependence On External Funding For PDS0101The decision to stop internally funding PDS0101’s Phase 3 program shifts its advancement onto partnerships or other outside capital. That dependence may delay development, reduce strategic control, or require economically costly arrangements if suitable funding is not secured on acceptable terms.
PDS Biotechnology News
EU6 FAQ
What was PDS Biotechnology Corporation’s price range in the past 12 months?
PDS Biotechnology Corporation lowest stock price was €0.17 and its highest was €1.22 in the past 12 months.
What is PDS Biotechnology Corporation’s market cap?
PDS Biotechnology Corporation’s market cap is €37.30M.
When is PDS Biotechnology Corporation’s upcoming earnings report date?
PDS Biotechnology Corporation’s upcoming earnings report date is Nov 12, 2026 which is in 38 days.
How were PDS Biotechnology Corporation’s earnings last quarter?
PDS Biotechnology Corporation released its earnings results on Aug 13, 2026. The company reported -€0.16 earnings per share for the quarter, missing the consensus estimate of -€0.116 by -€0.045.
Is PDS Biotechnology Corporation overvalued?
According to Wall Street analysts PDS Biotechnology Corporation’s price is currently Undervalued.
Does PDS Biotechnology Corporation pay dividends?
PDS Biotechnology Corporation does not currently pay dividends.
What is PDS Biotechnology Corporation’s EPS estimate?
PDS Biotechnology Corporation’s EPS estimate is -0.1.
How many shares outstanding does PDS Biotechnology Corporation have?
PDS Biotechnology Corporation has 55,971,336 shares outstanding.
What happened to PDS Biotechnology Corporation’s price movement after its last earnings report?
PDS Biotechnology Corporation reported an EPS of -€0.16 in its last earnings report, missing expectations of -€0.116. Following the earnings report the stock price went down -4.63%.
Which hedge fund is a major shareholder of PDS Biotechnology Corporation?
Currently, no hedge funds are holding shares in DE:EU6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PDS Biotechnology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.45 (2241.55% Upside)
€4.45 (2241.55% Upside)
Blogger Sentiment
Bullish
DE:EU6 Sentiment 100%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-78.24%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
PDS Biotechnology Corporation
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
EU6 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical and intellectual property progress: a strategic protocol amendment for VERSATILE-003 that reduces patient count (~28.6%) and time to an interim readout, peer-reviewed and encouraging clinical data for PDS01ADC, strengthened IP extending PDS0101 protection into the 2040s, and established manufacturing processes. Financially, operating expenses and net loss improved year-over-year. Key risks include a relatively modest cash balance ($21.7M), continued unprofitability with rising interest expense, the need for OS data for full approval and additional confirmatory trials, and competition in the HPV16 head and neck space. On balance, the operational and clinical positives outweigh the near-term financial and development risks.View all DE:EU6 earnings summariesEU6 Stock 12 Month Forecast
Average Price Target
€4.45
▲(2241.55% Upside)